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A method for measuring the effects of anticholinergics 
on histamine-induced bronchoconstriction in normal 
subjects. Oxitropium bromide provides dose-dependent 
protection 
O.-P. SEPPliLli 
Department of Clinical Pharmacology, University of Turku, Finland 
To study whether it would be possible to assess anticholinergic drugs in normal subjects with histamine- 
(HIST) induced bronchoconstriction, three doses of oxitropium bromide (100,200 and 400 pug) was inhaled in 
random order by twelve normal volunteers in a single-blind, placebo-controlled study. Dose response slope 
[DRS=maximal percentual fall in pulmonary function/maximal noncumulative histamine dose @mol)] was 
used as an index of bronchial reactivity, and was calculated for FEV, (DRSFEV,) and area under the 
flow-volume curve (DRS,,,,). The bronchial reactivity and its reproducibility was first tested with a standard 
provocation method. An abbreviated, single-dose, method was used in the measurement of the effects of 
oxitropium. The reproducibility of HIST-provocations were good with intraclass correlations of 0.97 and 0.99 
for logDRS,,vI and logDRS,,v, respectively. However, DRS,,,, seemed to be better in this respect as 
DRS,,v,. Also, the single-dose method gave results that were comparable to the standard one. 
The largest dose of oxitropium diminished the median DRS from 2.6 to 0.01 and from 5.2 to - 0.2 for FEV, 
and AEFV, respectively. All oxitropium doses differed significantly from placebo (PcO.01) and from each 
other (PcO.05) with DRS,,,v-values, but when DRS,,,, was used, a significant difference was detected only 
between placebo and active treatment (PcO.01). In conclusion, since the vagal mechanisms seem to be the 
predominant system mediating HIST-induced bronchoconstriction in normal subjects, it is possible with 
DRSAEFV to evaluate the efficacy of anticholinergics against HIST-induced bronchoconstriction in these 
subjects. 
Introduction 
Histamine (HIST) provocations are commonly 
used in evaluating the effects of bronchodilating 
drugs in asthmatic patients (l-3). However, asth- 
matic patients have a spontaneous variability of 
pulmonary function, and they may use other bron- 
chodilator or prophylactic drugs which can render 
difficult the precise and reliable measurement of the 
effect of the studied drug (4,5). Therefore, it would be 
more convenient to study normal volunteers in these 
trials. 
The information obtainable from studies on nor- 
mal subjects is, however, limited because of the low 
level of bronchial responsiveness in these subjects. 
This is especially true if the conventional method of 
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expressing results in provocative doses of broncho- 
constrictor causing a specified change in pulmonary 
function (e.g. PD,,FEV, or PD,,FEV,) is used. Even 
if a PD-value could be quantified at baseline con- 
ditions, airway reactivity may be unmeasurable after 
administration of bronchodilator drugs. 
O’Connor et al. (6) introduced for epidemiological 
purposes the dose-response slope (DRS, maximal 
percent decline in FEV,/ the dose of bronchoconstric- 
tor administered), which can be calculated in all 
situations and gives roughly the same information as 
the PD- or PC-values. It correlates closely with 
PD,,FEV, of histamine or methacholine (6,7). 
Although the DRS-values are highly reproducible in 
mixed populations of reactive and nonreactive sub- 
jects (7,8), Higgins et al. (7) questioned the value of 
DRS,,vI, since it is poorly reproducible in subjects in 
whom PD-values could not be obtained. 
We have previously successfully used the dose- 
response slope as a measure of airway responsiveness 
in pharmacological trials assessing &mimetics and 
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theophylline (9,lO) in normal subjects. In addition to 
FEV, DRS was calculated to the area under the 
expiratory flow-volume curve (AEFV), a pulmonary 
function parameter first introduced by Vermaak et al. 
(11). AEFV has been reported to be a sensitive and 
reliable indicator of bronchodilation (12,13) and 
induced bronchoconstriction (14,15). Both DRS,,,, 
and DRS,,,, have been found to be reliable and 
reproducible measures of airway responsiveness in 
pharmacological studies, although there is some 
evidence that DRSAEFv might be slightly a better 
reproducible index (10,14,15). 
The aim of this study was to compare the short- 
term reproducibility of DRS,,, and DRS,,,v, and 
their usefulness in assessing the effects of bronchodi- 
lating drugs against HIST-induced bronchoconstric- 
tion. Since there was contradictory data about the 
ability of anticholinergics to protect against HIST- 
induced bronchoconstriction in asthmatic patients 
(l-3, 1618) and the number of studies performed 
with normal subjects seems to be sparse (19), it was 
decided to study the effects of increasing doses of 
oxitropium bromide on HIST-provocation in normal 
subjects. 
Methods 
DESIGN 
The short term reproducibility of the HIST provo- 
cation was assessed with two provocations held 1 to 3 
days apart. One basis of these provocations a single 
optimum HIST-dose for each subject was determined 
to be used in the four consecutive drug-study days. 
Then, in a single-blind manner three different doses 
of oxitropium bromide and a placebo control were 
inhaled in random order on different occasions 2-3 
days apart, and their effects on airway reactivity was 
assessed. Each subject completed the study within a 
period of 2 weeks. 
SUBJECTS 
Twelve normal nonsmoking volunteers (Table 1) 
participated in the study. They had no personal or 
family history of asthma or other respiratory dis- 
eases, and their FEV, was greater than 80% of 
predicted (21). Three were mild atopics, indicated by 
a positive history of rhinitis or skin symptoms. They 
had never needed any treatment for their symptoms. 
None had symptoms of respiratory infections six 
weeks prior to or during the study. None of the 
subjects had any medication except oral contracep- 
tives a week prior to and during the study. In the 
morning of each study day, the subjects were allowed 
have a light breakfast, but caffeinated beverages were 
prohibited. All subjects gave informed consent, and 
the study was approved by the Ethics Committees 
of the Turku University and the Turku University 
Central Hospital. 
INSTRUMENTS AND DRUGS 
A pneumotachograph based computerized spi- 
rometer, Medikro 101s (Medikro Oy, Kuopio, 
Finland) with program version 2.4.5, was used to 
measure pulmonary function. HIST aerosols were 
delivered with an automatic, inhalation synchron- 
ized, dosimeter jet nebulizer, Spira Elektro 2 (Respir- 
atory Care Center, Haemeenlinna, Finland). It gives 
an airflow of 7.5 1 mini ’ through a standard Spira 
nebulizer to produce aerosol particles with a mass 
median aerodynamic diameter of 1.6 (geometric 
SD 1.4) pm (22). The dosimeter was adjusted to 
nebulize for 0.6 s. With these settings the mean f SD 
output of the nebulizer was 79.5 % 2.7,ul per five 
breaths, determined by five weighings before and 
after nebulizations. Thus, the mean * SD noncumu- 
lative dose of HIST ranged from 0.13 f 0.004 to 
4.15 % 0.14pmol per five breaths. Histamine dis- 
phosphate (Fluka Chemie, Buchs, Switzerland) 
was diluted with physiological saline to provide 
concentrations of 0.5, 2, 8 and 16 mg ml-‘. 
Placebo (carrier aerosol only) or oxitropium bro- 
mide (Ventox@, Leiras Pharmaceuticals, Turku) in 
doses of 100, 200 and 400 pg were administered from 
unlabelled metered dose inhalers (MDI) connected to 
a spacer device (Rondo @ Leiras Pharmaceuticals). , 
In order to optimize the amount of drug reaching the 
lungs a controlled inhalation technique was used: 
after shaking the canister the subjects expired to 
functional residual capacity (FRC) and took the 
mouthpiece of the spacer device firmly between the 
lips, triggered the MD1 to the spacer, and after a wait 
of 2-3 s took a slow and steady inhalation to total 
lung capacity (TLC), this was followed by 10 s breath 
holding. 
HISTAMINE PROVOCATIONS 
The control provocations for the assessment of 
reproducibility were executed according to the proto- 
col by Chai et al. (23) within a period of 3 days 
(mean & SD, 1.5 f 0.5 days). To avoid diurnal vari- 
ation, all provocations were performed at the same 
time of day. Each subject had practised the dosimeter 
nebulization and the pulmonary function measure- 
ments before the study. All procedures were per- 
formed with the subjects seated and wearing a 
noseclip. The subjects controlled their inhalations 
with a flow indicator and a digital readout so, that 
inspiratory rate reached but did not exceed 0.5 1 s- ‘. 
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The aerosols were inhaled with deep breaths from 
FRC to TLC following a breath holding period of 
10 s. 
Table 1 Anthropometric data of subjects (n=12) expressed 
as mean f SD (range) 
After performing four technically satisfactory 
baseline pulmonary function measurements, five 
breaths of saline diluent was inhaled and again four 
postsaline pulmonary function measurements were 
made. Subsequently, increasing concentrations of 
HIST aerosol at 5-min intervals were administered 
until FEV, fell 20% or more from the postsaline 
measurement, or the maximum concentration of 
16 mg ml-’ was reached. The highest dose of HIST 
given on this occasion was selected to be given as a 
single dose on the four successive drug trial days. 
FEV, and AEFV were used as estimates of pulmo- 
nary function. Pulmonary function tests were per- 
formed immediately and subsequently at 45-s 
intervals after the last inhalation of each HIST 
concentration until two technically correct manoeu- 
vres for the forced maximal expiratory flow-volume 
curves with a variation of less than 5% in the FEV, 
were obtained. Since the larger value at each 
stage was considered to represent a subject’s best 
potential lung function under the circumstances, 
from the two curves the better value of each variable 
was recorded. 
Male/Female 
Atopics/Non-atopics 
Age W 
Height (cm) 
Weight (kg) 
FEV, (1) 
FEV, of predicted (%) 
AEFV (1%‘) 
616 
319 
27.1 f 3.4 (22-34) 
174f3 (159%195) 
67.7 f 3.5 (5497) 
4.18 + 0.27 (29L6.15) 
98 zk 7 (83-l 14) 
24.3 zk 2.8 (13-746.3) 
DRS= 
Maximal decline in lung function (%) 
The maximum noncumulative dose of HIST 
inhaled @mol) 
MEASURING THE DRUG EFFECTS 
After performing the baseline and postsaline pul- 
monary function measurements, the oxitropium 
bromide dose was administered as described above. 
A 45-min interval was let to elapse allowing peak 
bronchodilation to occur (24) before taking five 
inhalations of the HIST dose selected previously on 
the basis of control provocations. Paired pulmonary 
function measurements were performed at l/2, 
2.1/2, 5, 10, 15, 20 min after the last inhalation of 
HIST and thereafter at 10 min intervals until the 
baseline was reached. The ambient temperature (“C) 
and relative humidity (%) were recorded on all 
study days. 
The results are presented as mean f SD, unless 
otherwise indicated. First, after the log,,- 
transformation of the data of the two first study days, 
the reproducibility of HIST-provocation was 
assessed by the method of Bland and Altman (25) 
and by intraclass correlations (ICC) (26). The abso- 
lute values of the differences in DRS-data obtained 
by this method [logDRS,,,v(day 2)-logDRS,,,v 
(day 1) and logDRS,,vl(day 2)-logDRS,,vl(day 1); 
no difference=ideal reproducibility] were subse- 
quently compared with a paired t-test. Since the data 
of the drug-trial days could not be normalized with 
transformations, Friedmans ANOVA and pairwise 
comparisons with Wilcoxon’s signed rank test with 
Bonferroni corrections were applied in the analysis of 
the dose-effects of oxitropium bromide. A PcO.05 
was considered as the limit of significance. The 
statistical analyses were performed with the BMDP 
statistical software package (BMDP Statistical 
Software Inc., Los Angeles, CA, USA). 
Results 
BASELINE MEASUREMENTS 
DATA ANALYSIS 
The decline in pulmonary function after each 
HIST dose was determined as follows: 
Decline (%)= 
Better postHIST value - Best postsaline value 
Best postsaline value 
x 100% 
The mean f SD and range of baseline pulmonary 
function values are presented in Table 1. The differ- 
ence in baseline values between the 6 study days did 
not exceed 5 and 11% of their mean for FEV, and 
AEFV, respectively. The ambient temperature (“C) 
and relative humidity (%) were 21.1 * 0.8”C and 
44.3 f 1.1% on the first day, and remained stable 
throughout the study; the variation in tempera- 
ture and humidity did not exceed 2°C and 3%, 
respectively. 
The dose response slopes for FEV, (DRS,,,J and CONTROL HISTAMINE PROVOCATIONS 
AEFV (DRS,,,,) were calculated from the follow- The mean f SD maximal percentage decline from 
ing formula (6): post-saline measurements was 15.3 f 13.8 (range 
276 O.-P. Seppdii 
$ 0.3 - 
r=l (a) 
t? 
(b) 
0.2 - - 4 Mean + 2s~ -________-____----__ 
a_ 0.1 - . Mean + 2s~ 2 l . . ------- CL-------------  
n 0.0 - . Mean - R 00 0 Mean 
3 
-j 
l 
. 
00 ” 0 ” 
-0.1 - 
0. 
---_ --------------~ Mean - 2s~ 
8 
8 
% 
-0.2 - Mean-2SD - 
b 
-____-____-____-----_ 
3 -@3 I , I I I 
0.5 1.0 1.5 06 1.0 1.5 
Average logDR&sv, between day 1 and 2 Average between day 1 and logDRSAEFv 2 
Fig. I The difference in logDRS-values between the two control provocations plotted against their mean. Panel A: 
logDR%,v, . Panel B: logDRSAEFv. The solid line indicates the mean difference, and the dashed lines limits of agreement 
(mean f 2 SD). 
5.9-53.7%) for FEV,, and 27.9 f 18.7 (14.9-785%) 
for AEFV. A measurable PD,,FEV, was obtained 
only from one atopic and one normal subject on both 
occasions. 
The short-term reproducibility of HIST- 
provocation assessed by DRS-values was good (Fig. 
1) with ICC-values of 0.97 and 0.99 for logDRS,,,, 
and logDRS,,,v, respectively. The mean differences 
for logDRS,nvI and logDRS,,, between the study 
days were -0.0293 and -0.0095, respectively. The 
corresponding 95% confidence interval (CI) for single 
measurements were f 0.062 and * 0.027. A paired 
t-test revealed that the absolute values of the dilfer- 
ences in logDRS,,,, (0.030 rt 0.031) scattered sig- 
nificantly less around zero (=ideal reproducibility) 
than differences in logDRS,,v, (0.085 f 0.049) 
(-2.98, P=O.O125, d.f.=ll). 
The single dose method gave slightly smaller DRS- 
values than the standard one, possibly due to differ- 
ences in the total histamine dose; the average 
difference ( YL 95% CI for single measurement) 
between the short and the average of control provo- 
cations was -0.106 ( f 0.129) and -0.059 (+ 0.112), 
for logDRS,,v, and logDRS,,,v, respectively. 
THE EFFECT OF OXITROPIUM BROMIDE ON BRONCHIAL 
REACTIVITY 
All oxitropium doses differed from placebo, and a 
significant trend towards a dose related effect in both 
DRS-values was observed [Friedman statistic 26.9 
and 29.7 (P<O.OOOl for both) for DRS,nv, and 
DRSAEFV, respectively] (Table 2, Figs 2 and 3) as the 
range of DRS-values of FEV, and AEFV after 
placebo shifted from 1.1-21.5 and 2.4-32.7 to 
- 1.8+10.0 and -2.6-+17.7 after the highest 
oxitropium dose, respectively. However, despite a 
tendency towards a dose-related effect, DRS,,, 
revealed a significant difference only between placebo 
and active treatment. On the other hand, DRS,nFV 
separated all the oxitropium doses from each other 
and placebo (PcO.05). 
Discussion 
The protective effect of oxitropium bromide 
against histamine-induced bronchoconstriction in 
normal subjects was evaluated using a simple method 
to measure airway responsiveness. 
Since initially only two of our 12 normal subjects 
experienced a decline of over 20% in FEV r , the use of 
the conventional index of airway responsiveness 
(PD,,FEV,) was not possible. Instead, the use of 
DRS-values provided estimates of responsiveness 
from all subjects, and after all doses of oxitropium. 
DR%w, was significantly less reproducible than 
DRSAEFW evidenced by the wider scatter of differ- 
ences in Fig. 1. This confirms the earlier evidence that 
DRSAEFV may be more reproducible than DRS,nV, 
in normal subjects (16), and that the reproducibility 
of DRSmv, may be poor in nonresponsive subjects 
(7,16). The better reproducibility of DRS,,,, when 
compared to DRS,,,, may be due to its wider range 
of response, since when the maximum response is 
limited, the within-subject variation and the measure- 
ment error are large when compared to the between- 
subject variation. 
By using DRS,,,, all three inhaled oxitropium 
doses (100, 200 and 400 pug) were discriminated from 
each other and from placebo. However, although a 
tendency towards a dose-related effect was seen 
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Table 2 Bronchial reactivity after different doses of oxitropium assessed by dose-response 
slope [DRS (%/pmol)] calculated from FEV, and area under the flow-volume curve (AEFV) 
(n=12) 
DR%,v, DRSAEFV 
Mean Median Range Mean Median Range 
Control 1 5.38 2.84 1.42-25.87 9.29 4.88 3.59-37.81 
Control 2 5.28 2.47 1.13-24.28 9.10 5.02 3,40-36.22 
Mean 5.33 265 1.37-25.07 9.09 4.95 3.62-37.01 
Placebo 4.31 2.58 1.13-21.48 7.69 5.19 2.41-32.75 
lOOPts 2.31 0.71 -0.51-19.65 3.65 0.82 -0.67-31.17 
2mPg 1.74 0.17 - 0.65-18.45 2.82 0.39 - 0.89-28.95 
400 Pg 0.83 0.01 - 1.78-9.97 1.19 - 0.24 -2.60-17.73 
Control 1 & 2=Control provocations. 
Mean=Mean of control 1 & 2. 
100-400 pg=Oxitropium bromide doses inhaled. 
Fig. 2 Dose response slopes of FEV, (% x prnol- ‘) after a control provocation (C, mean of the medians of two control 
provocations), placebo (P), and different doses of oxitropium presented as median values. Ns=not significant. *Differences 
between individual doses and placebo. 
(Table 2, Figs 2 and 3), DRS,,vI provided a statis- 
tically significant difference only between placebo 
and active treatment. A relatively small number of 
subjects were studied, and DRS,nVI might well have 
achieved significance if more subjects would have 
been included. In this case, however, possibly also 
higher levels of significance with DRS,,,, would 
have been obtained. Thus, the difference in the results 
between the two DRS-parameters can be explained 
with the poorer reproducibility of DRSFEv, when 
compared to DRS,,,,. 
A number of studies have investigated the effects of 
anticholinergics to bronchial responsiveness to hista- 
mine in asthmatic patients (l-3, 17-19). The protec- 
tion against histamine seems to be variable, and less 
marked than the protection offered by &mimetics. 
Only two studies have evaluated the effect of increas- 
ing doses of anticholinergics on bronchial responsive- 
ness (17,18). Despite evidence of marked 
bronchodilation, ipratropium offered no protection 
against histamine-induced bronchoconstriction in 
one study (17). According to another study (18) there 
appeared to be a maximum obtainable protection 
against histamine in asthmatic patients, since increas- 
ing the dose of ipratropium (40 pug+200 pug-+ 800 pg) 
did not provide any further protection after the initial 
dose. 
To our knowledge, only one group has previously 
studied the effects of anticholinergics on histamine- 
induced bronchoconstriction in normal subjects (20), 
no attempts to establish a dose-related effect has been 
made. The present study demonstrates a clear dose- 
dependent attenuation of bronchial responsiveness to 
histamine in normal subjects. Histamine has been 
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Fig. 3 Dose-response slopes of AEFV (% x pmol-‘) after a control provocation (C), placebo (P), and different doses of 
oxitropium bromide presented as median values. Symbols and explanations as in Fig. 2. 
suggested to cause bronchoconstriction through three 
mechanisms (27,28): First, by stimulating directly 
specific receptors on smooth muscle cells; Second, by 
stimulating the sensory nerve receptors leading to 
vagal reflexes; Third, by interacting with specific 
receptors on inflammatory cells leading to the lib- 
eration of inflammatory mediators, which in turn 
act on the smooth muscle cells or nerve receptors. It 
is possible, that in asthmatics the protective effect of 
anticholinergics on vagal reflexes is counteracted by 
the other two mechanisms, since epithelial damage 
(29) and inflammation (30) seen in asthma may 
increase the relative role of these mechanisms. The 
role of vagal innervation may vary with the extent 
of inflammation and epithelial damage. In normal 
subjects the airway epithelium is intact, and the 
vagal reflexes may have the major role in mediating 
histamine-induced bronchoconstriction. Since nine 
of our subjects were completely healthy, and only 
three had a mild atopy, it is reasonable to assume 
that they had no airway epithelial damage or 
inflammation. This might explain why complete and 
dose-dependent protection against histamine- 
induced bronchoconstriction was achieved in nor- 
mal subjects in the present study, but variable, and 
at most only partial protection in studies performed 
with asthmatic subjects (l-3, 17-19). Another, 
additional reason for this may be the inadequate 
function of the histamine receptor subtype 3 in 
asthmatics. The stimulation of H,-receptors is 
thought to protect against vagal bronchocon- 
striction (31). Thus, in normal subjects the H,- 
receptor stimulation together with the effects of 
anticholinergics may be sufficient enough to blunt 
the bronchoconstrictor effect of Hi-receptor stimu- 
lation. Other reasons for conflicting results in asth- 
matics may be the different dose-ranges of 
histamine and/or anticholinergic drugs used, and 
the method used to measure response, e.g. FEV, or 
SGAW. 
We did measure bronchodilation, because this 
would probably have uncovered the blindness of the 
study. One factor which theoretically might contrib- 
ute to the protective effect against histamine-induced 
bronchoconstriction is the bronchodilating effect of 
oxitropium, since it is well known that as airway 
calibre increases the response to inhaled bronchocon- 
strictor decreases (32). This is, however, unlikely, 
because most studies (3,17,18,20) have found no 
correlation between the protective effect of anticho- 
linergics and their bronchodilating effect, and the 
inhibition of bronchospasm is more likely to be due 
to the cholinergic properties of the anticholinergics 
than to nonspecific bronchodilation (20). 
In conclusion, the present study has demonstrated 
the use of a simple method of expressing the results 
of provocation studies in normal subjects, and 
DRSAEFV was found to be more reliable and repro- 
ducible a parameter than DRS,,, in these subjects. 
Also, a dose-related protection of oxitropium bro- 
mide against histamine-induced bronchoconstriction 
in normal subjects was found. This suggests, that 
cholinergic mechanisms have a major role in mediat- 
ing histamine-induced bronchoconstriction in these 
subjects. 
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